PV Reporter publishes roadmap to molecular remission in polycythemia vera

PV Reporter has released a patient education resource based on founder David Wallace’s six-year journey to undetectable disease in polycythemia vera, timed ahead of Blood Cancer Awareness Month. The guide is meant to help patients talk with doctors about driver mutations, treatment goals and specialist care.

Why it matters: - The new resource gives polycythemia vera patients a plain-language way to talk with physicians about molecular remission, treatment targets and the value of seeing an MPN specialist. - Blood Cancer Awareness Month begins in September, giving the publication added timing for patients seeking education and support. - Wallace’s case shows that deep remission can be possible in PV, while also underscoring that remission is not a cure and outcomes vary widely.

What happened: - PV Reporter published a patient education resource on August 11, 2026, centered on founder David Wallace’s path to complete molecular remission from polycythemia vera. - The resource is available here. - Wallace was diagnosed with PV in 2009. - His blood counts are normal, and the JAK2 mutation tied to his disease has remained undetectable for more than six years. - His JAK2 V617F allele burden fell from about 28% to undetectable.

The details: - The guide traces Wallace’s treatment progression from phlebotomy to pegylated interferon and then to combination therapy with ruxolitinib. - Wallace said research he found at the 2015 American Society of Hematology annual meeting led him to discuss the combination approach with his physician. - During treatment, Wallace developed skin cancer that required continued monitoring. - Wallace also experienced infections and repeated dose changes. - Wallace remains on low-dose maintenance therapy. - The resource says deep molecular responses have been reported with pegylated interferon alone and in combination with ruxolitinib. - The guide also points patients to PV Reporter’s free, doctor-vetted MPN Specialist Locator.

Between the lines: - Wallace spent years searching for a physician with strong MPN expertise and openness to current research. - He went through five hematologists early in his PV journey. - After asking the chief of hematology at his cancer center for “a doctor who knows more about PV than I do,” Wallace was referred to the specialist who still treats him. - The article frames specialist care as a practical issue, not just a preference, for patients navigating a complex rare cancer.

What’s next: - PV Reporter plans to keep focusing on patient-friendly education about myeloproliferative neoplasms. - The organization also maintains a free clinical trial finder and the specialist locator referenced in the new guide. - Wallace said newly diagnosed patients should learn what each treatment is meant to do and confirm they are seeing a true MPN specialist.

The bottom line: - PV Reporter is using Wallace’s experience to turn a rare, complex treatment story into a roadmap for other patients looking for better-informed care.